JPH09191856A - Nutrient-replenishing composition - Google Patents
Nutrient-replenishing compositionInfo
- Publication number
- JPH09191856A JPH09191856A JP8023030A JP2303096A JPH09191856A JP H09191856 A JPH09191856 A JP H09191856A JP 8023030 A JP8023030 A JP 8023030A JP 2303096 A JP2303096 A JP 2303096A JP H09191856 A JPH09191856 A JP H09191856A
- Authority
- JP
- Japan
- Prior art keywords
- milk
- calcium
- derived
- basic
- fraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 235000013336 milk Nutrition 0.000 claims abstract description 41
- 239000008267 milk Substances 0.000 claims abstract description 41
- 210000004080 milk Anatomy 0.000 claims abstract description 41
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000011575 calcium Substances 0.000 claims abstract description 31
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 31
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 claims abstract description 19
- 108090000284 Pepsin A Proteins 0.000 claims abstract description 7
- 102000057297 Pepsin A Human genes 0.000 claims abstract description 7
- 108091005804 Peptidases Proteins 0.000 claims abstract description 7
- 229940111202 pepsin Drugs 0.000 claims abstract description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000003729 cation exchange resin Substances 0.000 claims abstract description 4
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 235000015872 dietary supplement Nutrition 0.000 claims description 28
- 102000035195 Peptidases Human genes 0.000 claims description 6
- 108010019160 Pancreatin Proteins 0.000 claims description 5
- 229940055695 pancreatin Drugs 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 4
- 230000000593 degrading effect Effects 0.000 claims 1
- 210000002805 bone matrix Anatomy 0.000 abstract description 14
- 102000004169 proteins and genes Human genes 0.000 abstract description 10
- 108090000623 proteins and genes Proteins 0.000 abstract description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract description 5
- 208000001132 Osteoporosis Diseases 0.000 abstract description 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 241001474374 Blennius Species 0.000 abstract description 3
- 239000011347 resin Substances 0.000 abstract description 2
- 229920005989 resin Polymers 0.000 abstract description 2
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 229960005069 calcium Drugs 0.000 description 26
- 235000016709 nutrition Nutrition 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000000306 component Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229940088594 vitamin Drugs 0.000 description 9
- 229930003231 vitamin Natural products 0.000 description 9
- 235000013343 vitamin Nutrition 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 229910052500 inorganic mineral Inorganic materials 0.000 description 7
- 239000011707 mineral Substances 0.000 description 7
- 235000010755 mineral Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 150000004667 medium chain fatty acids Chemical class 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 238000000108 ultra-filtration Methods 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 108010073771 Soybean Proteins Proteins 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000257465 Echinoidea Species 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000237502 Ostreidae Species 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000005862 Whey Substances 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 108010046377 Whey Proteins Proteins 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 229960003563 calcium carbonate Drugs 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000020251 goat milk Nutrition 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 239000012533 medium component Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 235000014593 oils and fats Nutrition 0.000 description 2
- 235000020636 oyster Nutrition 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000001223 reverse osmosis Methods 0.000 description 2
- 235000020254 sheep milk Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000019710 soybean protein Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 101710197241 Accessory gland-specific peptide 70A Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000037180 bone health Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、カルシウム及び乳
由来塩基性ペプチドを配合した栄養補給用組成物に関す
る。本発明の栄養補給用組成物は、特に、高齢の患者等
への適用に好適であり、治療中の運動不足等に伴う骨粗
鬆症の予防乃至悪化防止効果を有する新しい組成の高齢
者向け経口経腸栄養補給用組成物として有用である。TECHNICAL FIELD The present invention relates to a nutritional supplement composition containing calcium and a milk-derived basic peptide. The composition for nutritional supplementation of the present invention is particularly suitable for application to elderly patients and the like, and a new composition of oral enteral administration for the elderly having an effect of preventing or aggravating osteoporosis associated with lack of exercise during treatment, etc. It is useful as a nutritional supplement composition.
【0002】[0002]
【従来の技術】栄養補給用組成物は、天然物由来の食品
素材やこれらを酸素等で種々の程度に分解した素材等を
配合して作られ、高カロリーで栄養的にバランスのとれ
た組成となっている。これらの栄養補給用組成物は、咀
嚼障害や消化管障害等の疾患がある場合や長期にわたる
栄養管理が必要な場合等にも使用され、このような目的
に適した種々の栄養補給用組成物が市販されている。そ
して今日までに、タンパク質、糖質、脂質、ビタミン、
ミネラル等をカロリー源や必須栄養素源とする栄養補給
用組成物が種々提案されている [特開平1-157364号公
報、特開平1-128919号公報、特開平2-119762号公報、特
開平3-103154号公報] 。しかしながら、このような栄養
補給用組成物を使用する対象者は主に手術後の患者であ
り、活動を制限されている場合が多い。また、適切な運
動と栄養管理は骨の健康にとって重要であることがよく
知られている。しかし、高齢者や閉経後の女性に見られ
る骨粗鬆症が近年顕在化し、問題となってきている。こ
れは、加齡に伴いカルシウム吸収能の低下、活性型ビタ
ミンD3 の分泌低下、ホルモンの不均衡等が起こるため
と考えられている。したがって、従来の栄養補給用組成
物のように、カルシウムとビタミンを考慮しただけでは
必ずしも充分とはいえなくなってきており、カルシウム
はもとより、カルシウムに次いで骨に多いコラーゲンを
主体とした骨基質にも考慮した栄養補給用組成物が求め
られている。2. Description of the Related Art A nutritional supplement composition is prepared by blending natural food-derived food materials and materials obtained by decomposing these to various degrees with oxygen, etc., and has a high calorie and nutritionally balanced composition. Has become. These nutritional supplement compositions are also used when there are diseases such as masticatory disorders and digestive tract disorders, and when long-term nutritional management is required, and various nutritional supplement compositions suitable for such purposes. Is commercially available. And to date, proteins, carbohydrates, lipids, vitamins,
Various compositions for nutritional supplementation have been proposed, in which minerals and the like are used as a calorie source or an essential nutrient source [JP-A 1-157364, JP-A 1-128919, JP-A 2-119762, and JP-A 3 -103154 publication]. However, the subjects using such a nutritional supplement composition are mainly patients after surgery, and their activities are often restricted. It is also well known that proper exercise and nutritional management are important for bone health. However, osteoporosis, which is seen in the elderly and postmenopausal women, has recently become apparent and has become a problem. It is considered that this is due to a decrease in the calcium absorption ability, a decrease in the secretion of active vitamin D 3 , a hormone imbalance, etc. with the treatment. Therefore, it is not always sufficient to consider calcium and vitamins as in conventional nutritional supplement compositions, and not only calcium but also bone matrix mainly composed of collagen, which is next to calcium in bone, is mainly used. There is a need for a nutritional supplement composition that is considered.
【0003】[0003]
【発明が解決しようとする課題】本発明者らは、食品素
材に含まれる骨基質を増加する成分や骨基質の減少を抑
制する成分について探索を進めていたところ、乳又は乳
由来原料を陽イオン交換体と接触させることにより得る
ことができる乳由来塩基性タンパク質画分にそのような
作用があることを見出し、また、この乳由来塩基性タン
パク質を経口摂取することにより骨代謝を改善できるこ
とを見出した [特願平6-261609号] 。DISCLOSURE OF THE INVENTION The present inventors have been searching for a component that increases the bone matrix and a component that suppresses the decrease of the bone matrix contained in food materials. It was found that the milk-derived basic protein fraction that can be obtained by contacting with an ion exchanger has such an action, and that orally ingesting this milk-derived basic protein can improve bone metabolism. I found it [Japanese Patent Application No. 6-261609].
【0004】そして、この乳由来塩基性タンパク質画分
中に含まれるラクトフェリン、ラクトパーオキシダーゼ
等の高分子タンパク質をペプシン、パンクレアチン等の
タンパク質分解酵素で予め加水分解して低分子化して
も、この骨基質を増加する活性や骨基質の減少を抑制す
る活性は全く失われないことを見出し、本発明を完成す
るに至った。したがって、本発明は、骨基質の増加を促
す成分や骨基質の減少を抑制する成分を配合した栄養バ
ランスの優れた栄養補給用組成物を提供することを課題
とする。Even if high molecular weight proteins such as lactoferrin and lactoperoxidase contained in the milk-derived basic protein fraction are hydrolyzed in advance by proteolytic enzymes such as pepsin and pancreatin to reduce the molecular weight, The inventors have found that the activity of increasing the bone matrix and the activity of suppressing the decrease of the bone matrix are not lost at all, and have completed the present invention. Therefore, an object of the present invention is to provide a nutritional supplement composition having an excellent nutritional balance, which contains a component that promotes an increase in bone matrix and a component that suppresses a decrease in bone matrix.
【0005】[0005]
【課題を解決するための手段】本発明の栄養補給用組成
物は、タンパク質、糖質、脂質、ビタミン類及びミネラ
ル類を主成分とするものであり、特にカルシウム及び乳
由来塩基性ペプチドを配合したものである。そして、好
ましくは、栄養補給用組成物中のカルシウム量に対し重
量比で 0.1〜10倍量となるよう乳由来塩基性ペプチドを
配合し、さらに好ましくは、栄養補給用組成物中のカル
シウム量が 0.1〜 1.0重量%となるようカルシウムを配
合する。The nutritional supplement composition of the present invention contains proteins, sugars, lipids, vitamins and minerals as main components, and particularly contains calcium and milk-derived basic peptides. It was done. Then, preferably, a milk-derived basic peptide is added so that the weight ratio is 0.1 to 10 times the amount of calcium in the nutritional supplement composition, and more preferably, the amount of calcium in the nutritional supplement composition is Calcium is added so that it becomes 0.1 to 1.0% by weight.
【0006】本発明の栄養補給用組成物に配合するカル
シウムとしては、乳又は乳由来原料から得られるカルシ
ウム [特開平6-125740号公報] 、海草由来カルシウム、
カキ殻、ウニ殻、イカ甲、魚骨等の海産物由来カルシウ
ム等、天然物由来カルシウムを使用することが好ましい
が、炭酸カルシウム、グルコン酸カルシウム、乳酸カル
シウム、クエン酸カルシウム、第3リン酸カルシウム等
のカルシウム塩を使用しても良い。[0006] As calcium to be added to the nutritional supplement composition of the present invention, calcium obtained from milk or milk-derived raw material [JP-A-6-125740], seaweed-derived calcium,
It is preferable to use calcium derived from natural products such as calcium derived from marine products such as oyster shells, sea urchin shells, squid shells and fish bones, but calcium such as calcium carbonate, calcium gluconate, calcium lactate, calcium citrate and tricalcium phosphate. You may use salt.
【0007】また、本発明の栄養補給用組成物に配合す
る乳由来塩基性ペプチドとしては、牛乳、人乳、山羊
乳、羊乳等、哺乳類動物の乳から得られる乳由来塩基性
タンパク質画分、好ましくは、そのアミノ酸組成中に塩
基性アミノ酸を15重量%以上含有している画分をペプシ
ン、パンクレアチン等のタンパク質分解酵素で予め加水
分解し、必要に応じ限外濾過膜処理等で分子量を2万以
下にした乳由来塩基性ペプチド画分を使用する。次に、
乳由来塩基性ペプチド画分を製造する方法について以下
に説明する。The milk-derived basic peptide contained in the nutritional supplement composition of the present invention includes milk-derived basic protein fractions obtained from milk of mammals such as cow milk, human milk, goat milk, and sheep milk. , Preferably, the fraction containing 15% by weight or more of basic amino acids in the amino acid composition is previously hydrolyzed with a proteolytic enzyme such as pepsin or pancreatin, and the molecular weight is adjusted by ultrafiltration membrane treatment, if necessary. A milk-derived basic peptide fraction having a content of 20,000 or less is used. next,
The method for producing the milk-derived basic peptide fraction will be described below.
【0008】まず、乳由来塩基性タンパク質画分を調製
する。乳由来塩基性タンパク質画分を得る方法として
は、乳又は乳由来原料を陽イオン交換体に接触させて塩
基性タンパク質を吸着させた後、この陽イオン交換体に
吸着した塩基性タンパク質を、pH5を越え、かつイオン
強度 0.5を越える溶出液で溶出して得る方法 [特開平5-
202098号公報] 、アルギン酸ゲルを用いて得る方法 [特
開昭 61-246198号公報]、硫酸化エステルを用いて乳か
ら得る方法 [特開昭 63-255300号公報] 、無機多孔質粒
子を用いて乳清から得る方法 [特開平1- 86839号公報]
、あるいは、ウシインスリン様成長因子−1含有物を
製造する方法 [特願平6- 85333号] 等が知られている。
そして、このような方法で得られた乳由来塩基性タンパ
ク質画分を、例えば、塩酸溶液にてpH 1.5に調整し、ペ
プシン等のタンパク質分解酵素で加水分解した後、水酸
化ナトリウム等のアルカリ溶液を加えて中和することに
より塩基性ペプチド画分を得ることができる。なお、乳
由来塩基性タンパク質画分の加水分解に際しては、パン
クレアチン等のタンパク質分解酵素を加え、加水分解を
より確実にしておくことが好ましい。このようにして得
られた乳由来塩基性ペプチド画分は、さらに、イオン交
換法、逆浸透法、限外濾過法、電気透析法等の手段で脱
塩及び濃縮し、必要に応じ凍結乾燥法や噴霧乾燥法等の
手段で乾燥して栄養補給用組成物に配合する。First, a milk-derived basic protein fraction is prepared. As a method for obtaining a milk-derived basic protein fraction, milk or a milk-derived raw material is brought into contact with a cation exchanger to adsorb the basic protein, and then the basic protein adsorbed on the cation exchanger is adjusted to pH 5 And elution with an eluent having a ionic strength of more than 0.5 [JP-A-HEI 5-
202098], a method using an alginic acid gel [JP-A-61-246198], a method using milk with a sulfated ester [JP-A-63-255300], using inorganic porous particles To obtain from whey [JP-A-1-86839]
Alternatively, a method for producing a bovine insulin-like growth factor-1 containing substance [Japanese Patent Application No. 6-85333] is known.
Then, the milk-derived basic protein fraction obtained by such a method is adjusted to pH 1.5 with a hydrochloric acid solution, hydrolyzed with a proteolytic enzyme such as pepsin, and then alkali solution such as sodium hydroxide. A basic peptide fraction can be obtained by adding and neutralizing. When the milk-derived basic protein fraction is hydrolyzed, it is preferable to add a proteolytic enzyme such as pancreatin to ensure the hydrolysis. The milk-derived basic peptide fraction thus obtained is further desalted and concentrated by a means such as an ion exchange method, a reverse osmosis method, an ultrafiltration method, an electrodialysis method, and if necessary, a freeze-drying method. Or a spray-drying method or the like to dry and blend it into the nutritional supplement composition.
【0009】[0009]
【発明の実施の形態】本発明の栄養補給用組成物の主成
分は、タンパク質、糖質、脂質、ビタミン類及びミネラ
ル類である。タンパク質としては、消化し易く栄養価の
高いもの、例えば、乳タンパク質、鶏卵タンパク質、大
豆タンパク質、あるいは、これらタンパク質の分解物で
あるペプチドやアミノ酸等を使用すれば良い。糖質とし
ては、デキストリン、ブドウ糖、果糖、マルトース、乳
糖等を使用すれば良い。脂質としては、植物油や中鎖脂
肪酸トリグリセリド等を使用することが好ましく、植物
油としては、リノール酸やα−リノレン酸を含有する大
豆油、ナタネ油、エゴマ油、シソ油、パーム油等を使用
すれば良い。なお、中鎖脂肪酸トリグリセリドとは、炭
素数6〜12個の中鎖脂肪酸が結合したトリグリセリドで
あり、通常の油脂類と比べ消化吸収性が優れていること
が知られている。そして、使用目的や使用形態により変
更可能であるが、通常、タンパク質を約15〜40重量%、
糖質を約50〜80重量%及び脂質を約10〜25重量%の割合
で混合すれば良い。さらに、必要に応じ、ビタミン類と
して、通常、栄養剤等に使用されるビタミン、例えば、
ビタミンA、ビタミンD、ビタミンE、ビタミンK、ビ
タミンB1 、ビタミンB2 、ビタミンB6 、ビタミンB
12、ビタミンC、葉酸、ナイアシン、パントテン酸、コ
リン、イノシトール、ニコチン酸アミド等を使用すれば
良く、また、ミネラル類として、ナトリウム、カリウ
ム、カルシウム、マグネシウム、リン、鉄、イオウ等を
使用すれば良い。BEST MODE FOR CARRYING OUT THE INVENTION The main components of the nutritional supplement composition of the present invention are proteins, sugars, lipids, vitamins and minerals. As the protein, those that are easily digested and have a high nutritional value, such as milk protein, chicken egg protein, soybean protein, or peptides or amino acids which are degradation products of these proteins may be used. As the sugar, dextrin, glucose, fructose, maltose, lactose or the like may be used. As the lipid, it is preferable to use vegetable oil or medium-chain fatty acid triglyceride, and the like.As the vegetable oil, soybean oil containing linoleic acid or α-linolenic acid, rapeseed oil, perilla oil, perilla oil, palm oil, etc. may be used. Good. The medium-chain fatty acid triglyceride is a triglyceride in which a medium-chain fatty acid having 6 to 12 carbon atoms is bonded, and it is known that the medium-chain fatty acid triglyceride has a better digestive absorbability than ordinary fats and oils. And, although it can be changed depending on the purpose of use and usage form, usually about 15 to 40% by weight of protein,
The sugar may be mixed in a ratio of about 50 to 80% by weight and the lipid may be mixed in a ratio of about 10 to 25% by weight. Furthermore, if necessary, as vitamins, vitamins normally used in nutritional supplements, for example,
Vitamin A, Vitamin D, Vitamin E, Vitamin K, Vitamin B 1 , Vitamin B 2 , Vitamin B 6 , Vitamin B
12 , vitamin C, folic acid, niacin, pantothenic acid, choline, inositol, nicotinic acid amide, etc. may be used, and as minerals, sodium, potassium, calcium, magnesium, phosphorus, iron, sulfur, etc. may be used. good.
【0010】そして、上述したようなタンパク質、糖
質、脂質、ビタミン類及びミネラル類を主成分とする栄
養補給用組成物に、カルシウムとして、乳由来カルシウ
ム、海草由来カルシウム、カキ殻、ウニ、イカ甲、魚骨
等の海産物由来カルシウム等の天然物由来カルシウムや
炭酸カルシウム、グルコン酸カルシウム、乳酸カルシウ
ム、クエン酸カルシウム、第3リン酸カルシウム等のカ
ルシウム化合物等を、乳由来塩基性ペプチドとして、牛
乳、人乳、山羊乳、羊乳等、哺乳類動物の乳から得られ
る乳由来塩基性タンパク質画分、好ましくは、そのアミ
ノ酸組成中に塩基性アミノ酸を15重量%以上含有してい
る画分をペプシンやパンクレアチン等のタンパク質分解
酵素で予め加水分解し、必要に応じ限外濾過膜処理等で
分子量を2万以下にした乳由来塩基性ペプチド画分を、
それぞれ配合する。なお、乳由来塩基性ペプチドは、栄
養補給用組成物中に含まれるカルシウム量に対し重量比
で 0.1〜10倍量となるよう栄養補給用組成物に配合すれ
ば良く、好ましくは、栄養補給用組成物中に含まれるカ
ルシウム量が 0.1〜 1.0重量%となるようカルシウムを
配合すれば良い。In the nutritional supplement composition containing the above-mentioned proteins, sugars, lipids, vitamins and minerals as the main components, calcium derived from milk, calcium derived from seaweeds, oyster shells, sea urchins and squids are used as calcium. Shells, calcium derived from natural products such as calcium derived from marine products such as fish bones, calcium carbonate, calcium gluconate, calcium lactate, calcium citrate, tribasic calcium phosphate, etc. as milk-derived basic peptides, milk, human Milk, goat milk, milk-derived basic protein fraction derived from milk of mammals such as sheep milk, preferably a fraction containing 15% by weight or more of basic amino acids in its amino acid composition is pepsin or bread. Preliminarily hydrolyzed with a proteolytic enzyme such as creatine, and if necessary, reduce the molecular weight to 20,000 or less by ultrafiltration membrane treatment. And the milk-derived basic peptide fraction,
Add each. The milk-derived basic peptide may be added to the nutritional supplement composition in a weight ratio of 0.1 to 10 times the amount of calcium contained in the nutritional supplement composition. Calcium may be added so that the amount of calcium contained in the composition is 0.1 to 1.0% by weight.
【0011】また、本発明の栄養補給用組成物は、栄養
成分が水中に溶解や乳化している液状物の形態で提供し
ても良く、乾燥して粉末や顆粒の形態で提供しても良
い。なお、粉末状又は顆粒状の栄養補給用組成物は、経
口経腸投与時に水中、好ましくは40〜60℃の温水中に投
入し、撹拌、溶解して使用する。この場合、水溶液のカ
ロリーが 0.5〜1.5kcal/mlとなるよう20〜25%(w/v) 前
後になるよう溶解することが好ましい。さらに、経腸投
与する場合には、水分の必要量を考慮し、1日当たり
1,500〜2,500ml 投与とすることが好ましく、経口投与
する場合には、 400〜500ml の溶液に栄養補給用組成物
90〜100gを溶解し、滅菌した缶等の容器に充填した飲料
の形態でカロリー必要量に応じて食事と併用することも
できる。The nutritional supplement composition of the present invention may be provided in the form of a liquid in which the nutrient components are dissolved or emulsified in water, or may be dried and provided in the form of powder or granules. good. The powdery or granular composition for nutritional supplementation is put into water, preferably 40 to 60 ° C. warm water at the time of oral enteral administration, and is stirred and dissolved before use. In this case, it is preferable to dissolve the aqueous solution so that the calorie of the aqueous solution becomes about 0.5 to 1.5 kcal / ml and about 20 to 25% (w / v). Furthermore, in the case of enteral administration, consider the necessary amount of water and
It is preferable to administer 1,500 to 2,500 ml, and for oral administration, add 400 to 500 ml of the solution to the nutritional supplement composition.
It can also be used in combination with a meal in the form of a beverage prepared by dissolving 90 to 100 g and filling a container such as a sterilized can according to the calorie requirement.
【0012】[0012]
【参考例1】陽イオン交換樹脂のスルホン化キトパール
(富士紡績製)400gを充填したカラムに、未殺菌チーズ
ホエー40リットルを通液した後、このカラムを脱イオン
水で洗浄し、 0.98M塩化ナトリウムを含む 0.02M炭酸緩
衝液(pH 7.0)で樹脂に吸着した塩基性タンパク質画分を
溶出した。この塩基性タンパク質画分を塩酸溶液でpH1.
5に調整した後、ペプシン (関東化学製) を2%濃度と
なるよう添加し、37℃で1時間撹拌しながら加水分解し
た。次いで、水酸化ナトリウム溶液でpH 6.8に中和後、
パンクレアチン (和光純薬製) を 0.5%濃度となるよう
添加し、37℃で1時間撹拌しながら加水分解した。そし
て、85℃で10分間加熱して酵素を失活させた。この塩基
性タンパク質画分の加水分解物を分子量分画20,000の限
外濾過膜で処理し、その透過液を逆浸透膜で処理して脱
塩、濃縮した後、凍結乾燥して粉末状の塩基性ペプチド
画分 15gを得た。なお、この塩基性ペプチド画分の成分
組成を表1に、また、この塩基性ペプチド画分中に含ま
れるアミノ酸の組成を表2に、それぞれ示す。[Reference Example 1] After passing 40 liters of unpasteurized cheese whey through a column filled with 400 g of cation exchange resin sulfonated chitopearl (manufactured by Fuji Boseki), this column was washed with deionized water to obtain 0.98 M chloride. The basic protein fraction adsorbed on the resin was eluted with 0.02 M carbonate buffer (pH 7.0) containing sodium. This basic protein fraction was adjusted to pH 1. with a hydrochloric acid solution.
After adjusting to 5, pepsin (manufactured by Kanto Kagaku) was added so as to have a concentration of 2%, and hydrolysis was carried out at 37 ° C. for 1 hour with stirring. Then, after neutralizing to pH 6.8 with sodium hydroxide solution,
Pancreatin (manufactured by Wako Pure Chemical Industries, Ltd.) was added so as to have a concentration of 0.5% and hydrolyzed while stirring at 37 ° C. for 1 hour. Then, the enzyme was inactivated by heating at 85 ° C for 10 minutes. The hydrolyzate of this basic protein fraction was treated with an ultrafiltration membrane with a molecular weight fraction of 20,000, and the permeate was treated with a reverse osmosis membrane for desalting and concentration, and then freeze-dried to give a powdery base. 15 g of the sex peptide fraction was obtained. The component composition of this basic peptide fraction is shown in Table 1, and the composition of the amino acids contained in this basic peptide fraction is shown in Table 2.
【0013】[0013]
【表1】 ───────────────── 水分 1.0 (重量%) タンパク質 97.0 脂肪 0.4 灰分 0.3 その他 1.3 ─────────────────[Table 1] ───────────────── Moisture 1.0 (wt%) Protein 97.0 Fat 0.4 Ash 0.3 Other 1.3 ─────────────── ──
【0014】[0014]
【表2】 ────────────────── アスパラギン酸 11 (重量%) セリン 5 グルタミン酸 12 プロリン 6 アラニン 6 ロイシン 10 リジン 9 ヒスチジン 3 アルギニン 8 その他 30 ──────────────────[Table 2] ────────────────── Aspartic acid 11 (wt%) Serine 5 Glutamic acid 12 Proline 6 Alanine 6 Leucine 10 Lysine 9 Histidine 3 Arginine 8 Other 30 ─── ───────────────
【0015】[0015]
【試験例1】参考例1で得られた塩基性ペプチド画分に
ついて、骨基質産生促進効果を調べた。すなわち、培養
骨芽細胞様株(MC3T3-E1)を96穴の平底細胞培養プレート
に撒き込み、 0.2重量%のウシ血清を含むα−MEM培
地(Flow Laboratories社製)で18時間培養した (対照群)
。なお、試験群には培地 100μl に対し、塩基性ペプ
チド画分が 0.5重量%となるよう溶解した溶液2μl を
添加した。そして、培養後、PBS溶液で培地成分を洗
浄し、骨芽細胞が産生したコラーゲン量をコラーゲンに
特異的なアミノ酸であるハイドロキシプロリン量を測定
することにより求めた。その結果を図1に示す。この結
果から明らかなように、塩基性ペプチド画分を添加した
試験群では、培地成分のみの対照群に比較し、2倍以上
のコラーゲンが産生されていることが認められた。Test Example 1 With respect to the basic peptide fraction obtained in Reference Example 1, the effect of promoting bone matrix production was examined. That is, the cultured osteoblast-like cell line (MC3T3-E1) was seeded on a 96-well flat-bottom cell culture plate, and cultured for 18 hours in α-MEM medium (manufactured by Flow Laboratories) containing 0.2% by weight of bovine serum (control). group)
. To the test group, 2 μl of a solution prepared by dissolving the basic peptide fraction at 0.5% by weight in 100 μl of the medium was added. Then, after culturing, the medium components were washed with a PBS solution, and the amount of collagen produced by osteoblasts was determined by measuring the amount of hydroxyproline, which is a collagen-specific amino acid. The result is shown in FIG. As is clear from these results, it was confirmed that the test group to which the basic peptide fraction was added produced twice or more collagen as compared with the control group containing only the medium components.
【0016】[0016]
【実施例1】参考例1で得られた塩基性ペプチド画分を
配合し、表3に示す配合割合で栄養補給用組成物を調製
した。すなわち、水60kg中に、乳タンパク質 3.4kg、大
豆タンパク質 1.1kg及び塩基性ペプチド画分0.04kgを分
散し、70℃まで加温して溶解した後、この溶液にデキス
トリン12.4kgを添加して溶解した。さらに、この溶液に
油脂類 2.4kg及び大豆レシチン 0.2kgを添加し、TKホ
モミキサーで予備乳化した後、濃縮し、噴霧乾燥して粉
末を得た。そして、この粉末に適当量のミネラル類、ビ
タミン類及び香料を添加し、混合して粉末の栄養補給用
組成物15kgを得た。Example 1 The basic peptide fraction obtained in Reference Example 1 was blended to prepare a nutritional supplement composition at the blending ratio shown in Table 3. That is, in 60 kg of water, 3.4 kg of milk protein, 1.1 kg of soybean protein and 0.04 kg of basic peptide fraction were dispersed, heated to 70 ° C and dissolved, and then 12.4 kg of dextrin was added to this solution to dissolve. did. Furthermore, 2.4 kg of oils and fats and 0.2 kg of soybean lecithin were added to this solution, preliminarily emulsified with a TK homomixer, then concentrated and spray dried to obtain a powder. Then, appropriate amounts of minerals, vitamins and flavors were added to this powder and mixed to obtain 15 kg of powdered nutritional supplement composition.
【0017】[0017]
【表3】 ────────────────────────────── 乳タンパク質 17.2 (重量%) 大豆タンパク質 5.7 塩基性ペプチド画分 0.2 油脂類(大豆油、パーム油、精製魚油) 11.9 大豆レシチン 1.1 デキストリン 62.0 ビタミン類 0.1 ミネラル類 2.8 (カルシウム 0.2) 香料 適量 ──────────────────────────────[Table 3] ────────────────────────────── Milk protein 17.2 (wt%) Soy protein 5.7 Basic peptide fraction 0.2 Oils and fats (soybean oil, palm oil, refined fish oil) 11.9 Soybean lecithin 1.1 Dextrin 62.0 Vitamins 0.1 Minerals 2.8 (calcium 0.2) Perfume Suitable amount ───────────────────── ──────────
【0018】[0018]
【試験例2】実施例1で得られた本発明の栄養補給用組
成物粉末と、塩基性ペプチド画分を添加しないこと以外
は同様の配合で製造した対照粉末とについて、ラットを
用い骨基質量への影響を調べた。すなわち、それぞれ27
g/100ml となるよう各粉末を温湯で溶解した。一方、6
週齢SD系雌ラット6匹をエーテル麻酔下で開腹し、胃
底部に内径 0.8mmのポリエチレンチューブを装着した。
胃カテーテル装着後、ラットはボールマンケージ拘束下
で保持した。本発明群及び対照群それぞれ3匹ずつと
し、胃内にそれぞれの栄養補給用組成物をシリンジポン
プで3ml/hrの速度により2週間連続的に注入した。2週
間経過後、ラットの大腿骨を摘出し、常法により骨中の
アミノ酸量を測定して骨基質量の指標とした。その結果
を図2に示す。この結果によると、本発明群では、対照
群に比べ、骨基質(コラーゲン)の構成アミノ酸である
プロリン及びハイドロキシプロリン量が統計的有意に多
いことが認められた。Test Example 2 The composition powder for nutritional supplementation of the present invention obtained in Example 1 and the control powder produced by the same formulation except that the basic peptide fraction was not added, were used as the bone matrix in rats. The effect on mass was investigated. Ie 27 each
Each powder was dissolved in warm water so that the concentration was g / 100 ml. On the other hand, 6
Six 6-week-old SD female rats were laparotomized under ether anesthesia, and a polyethylene tube with an inner diameter of 0.8 mm was attached to the fundus.
After mounting the gastric catheter, the rat was kept under Bolmann cage restraint. Each of the present invention group and the control group was made up of 3 animals, and each nutritional supplement composition was continuously infused into the stomach with a syringe pump at a rate of 3 ml / hr for 2 weeks. After 2 weeks, the femur of the rat was removed and the amount of amino acid in the bone was measured by a conventional method to be used as an index of the mass of bone base. The result is shown in FIG. From these results, it was confirmed that the amounts of proline and hydroxyproline, which are the constituent amino acids of bone matrix (collagen), were statistically significantly higher in the group of the present invention than in the control group.
【0019】[0019]
【発明の効果】本発明の栄養補給用組成物は、骨基質の
増加を促す作用、あるいは、骨基質の減少を抑制する作
用を有するので、これを摂取することにより、骨粗鬆症
や骨折時等の栄養補給はもとより、手術後の拘束下での
運動不足に伴う骨量や骨基質の低下を予防することがで
きる。また、閉経後の女性や高齢者のための栄養補給用
食品として摂取することにより、骨粗鬆症の悪化を防止
することができる。INDUSTRIAL APPLICABILITY The composition for nutritional supplementation of the present invention has an action of promoting an increase in bone matrix or an action of suppressing a decrease in bone matrix. Therefore, by ingesting the composition, it is possible to prevent osteoporosis and fracture. In addition to nutritional support, it is possible to prevent a decrease in bone mass and bone matrix due to lack of exercise under restraint after surgery. Further, by ingesting it as a nutritional supplement food for post-menopausal women and the elderly, deterioration of osteoporosis can be prevented.
【図1】試験例1のカルシウムと乳由来塩基性ペプチド
画分とによるコラーゲン産生促進作用を示す。FIG. 1 shows the collagen production promoting action of calcium and milk-derived basic peptide fraction of Test Example 1.
【図2】試験例2の本発明栄養補給用組成物の大腿骨基
質増加作用を示す。FIG. 2 shows the effect of increasing the femoral matrix of the nutritional supplement composition of the present invention in Test Example 2.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 庁内整理番号 FI 技術表示箇所 // A61K 33/06 ABJ A61K 33/06 ABJ 35/20 35/20 38/00 ADD 37/18 ADD ─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. 6 Identification code Internal reference number FI technical display location // A61K 33/06 ABJ A61K 33/06 ABJ 35/20 35/20 38/00 ADD 37/18 ADD
Claims (5)
配合したことを特徴とする栄養補給用組成物。1. A nutritional supplement composition comprising calcium and a milk-derived basic peptide.
で 0.1〜10倍量の乳由来塩基性ペプチドを配合する請求
項1記載の組成物。2. The composition according to claim 1, wherein the milk-derived basic peptide is added in a weight ratio of 0.1 to 10 times the amount of calcium in the composition.
量%である請求項1又は2記載の組成物。3. The composition according to claim 1, wherein the amount of calcium in the composition is 0.1 to 1.0% by weight.
原料を陽イオン交換樹脂に接触させて塩基性タンパク質
を吸着させた後、塩濃度 0.1〜1.0Mの溶出液で溶出して
得られる塩基性タンパク質画分をタンパク質分解酵素で
分解して得られる塩基性ペプチド画分である請求項1〜
3のいずれかに記載の組成物。4. A milk-derived basic peptide is obtained by contacting milk or a milk-derived raw material with a cation exchange resin to adsorb a basic protein, and then eluting it with an eluate having a salt concentration of 0.1 to 1.0M. A basic peptide fraction obtained by degrading a basic protein fraction with a proteolytic enzyme.
4. The composition according to any one of 3.
原料を陽イオン交換樹脂に接触させて塩基性タンパク質
を吸着させた後、塩濃度 0.1〜1.0Mの溶出液で溶出して
得られる塩基性画分をペプシンで分解し、さらにパンク
レアチンで分解して得られる分子量約 2,000〜20,000の
塩基性ペプチド画分である請求項1〜4のいずれかに記
載の組成物。5. A milk-derived basic peptide is obtained by contacting milk or a milk-derived raw material with a cation exchange resin to adsorb a basic protein and then eluting it with an eluate having a salt concentration of 0.1 to 1.0M. The composition according to any one of claims 1 to 4, which is a basic peptide fraction having a molecular weight of about 2,000 to 20,000 obtained by decomposing a basic fraction with pepsin and further decomposing it with pancreatin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP02303096A JP3613488B2 (en) | 1996-01-17 | 1996-01-17 | Nutritional composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP02303096A JP3613488B2 (en) | 1996-01-17 | 1996-01-17 | Nutritional composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09191856A true JPH09191856A (en) | 1997-07-29 |
JP3613488B2 JP3613488B2 (en) | 2005-01-26 |
Family
ID=12099084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP02303096A Expired - Fee Related JP3613488B2 (en) | 1996-01-17 | 1996-01-17 | Nutritional composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3613488B2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0948569A4 (en) * | 1996-12-24 | 1999-11-24 | ||
WO2004050116A1 (en) * | 2002-11-29 | 2004-06-17 | Morinaga Milk Industry Co., Ltd. | Protease inhibitor |
JP2004331565A (en) * | 2003-05-07 | 2004-11-25 | Snow Brand Milk Prod Co Ltd | Skin collagen production enhancer |
JP2004331564A (en) * | 2003-05-07 | 2004-11-25 | Snow Brand Milk Prod Co Ltd | Skin collagen production enhancer |
US7749960B2 (en) | 2001-04-03 | 2010-07-06 | Nestec S.A. | Osteoprotegerin in milk |
JP2010180219A (en) * | 2010-03-04 | 2010-08-19 | Snow Brand Milk Prod Co Ltd | Lactoferrin composition |
WO2014020684A1 (en) * | 2012-07-31 | 2014-02-06 | 雪印メグミルク株式会社 | Cheese and method for producing same |
WO2014157156A1 (en) * | 2013-03-28 | 2014-10-02 | 雪印メグミルク株式会社 | Protein composition and production process therefor |
-
1996
- 1996-01-17 JP JP02303096A patent/JP3613488B2/en not_active Expired - Fee Related
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0948569A4 (en) * | 1996-12-24 | 1999-11-24 | ||
US7749960B2 (en) | 2001-04-03 | 2010-07-06 | Nestec S.A. | Osteoprotegerin in milk |
WO2004050116A1 (en) * | 2002-11-29 | 2004-06-17 | Morinaga Milk Industry Co., Ltd. | Protease inhibitor |
JP2004331565A (en) * | 2003-05-07 | 2004-11-25 | Snow Brand Milk Prod Co Ltd | Skin collagen production enhancer |
JP2004331564A (en) * | 2003-05-07 | 2004-11-25 | Snow Brand Milk Prod Co Ltd | Skin collagen production enhancer |
JP4698934B2 (en) * | 2003-05-07 | 2011-06-08 | 雪印乳業株式会社 | Skin collagen production promoter |
JP2010180219A (en) * | 2010-03-04 | 2010-08-19 | Snow Brand Milk Prod Co Ltd | Lactoferrin composition |
WO2014020684A1 (en) * | 2012-07-31 | 2014-02-06 | 雪印メグミルク株式会社 | Cheese and method for producing same |
US10485853B2 (en) | 2012-07-31 | 2019-11-26 | Megmilk Snow Brand Co., Ltd. | Cheese and method for producing the same |
WO2014157156A1 (en) * | 2013-03-28 | 2014-10-02 | 雪印メグミルク株式会社 | Protein composition and production process therefor |
JP2014193125A (en) * | 2013-03-28 | 2014-10-09 | Snow Brand Milk Products Co Ltd | Protein composition, and method for manufacturing the same |
US9861121B2 (en) | 2013-03-28 | 2018-01-09 | Megmilk Snow Brand Co., Ltd. | Milk basic protein composition and production process therefor |
Also Published As
Publication number | Publication date |
---|---|
JP3613488B2 (en) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3112637B2 (en) | Bone strengthener | |
US20120040908A1 (en) | Fracture repair promoter | |
ES2215940T3 (en) | BASIC PROTEIN TRACTION DERIVED FROM MILK AS AN AGENT TO REDUCE HYPERTENSION. | |
WO2005016373A1 (en) | Osteogenesis promoter | |
JPH09227403A (en) | Osteogenic promoting and bone resorption preventing agent | |
JP3613488B2 (en) | Nutritional composition | |
JP6410909B2 (en) | Cartilage formation promoter | |
JPWO2009057287A1 (en) | Food material for inhibiting osteoclast formation | |
CA2704144C (en) | Food material for promoting the differentiation of osteoblast and inhibiting the differentiation of osteoclast | |
JP5357042B2 (en) | Bone strengthening food material | |
TWI607709B (en) | Bone strengthening agent | |
JP2004115509A (en) | Osteoprotegerin inhibitory factor production promoter | |
JP3578538B2 (en) | Baby Food | |
JPWO2009057282A1 (en) | Food material for suppressing bone resorption | |
JP3061364B2 (en) | Infant formula | |
JP4034516B2 (en) | Lipid metabolism improver | |
JP4028177B2 (en) | Antihypertensive | |
US20190091304A1 (en) | Novel protein material | |
TWI804459B (en) | Use of lactoperoxidase, cystatin, hmg protein and/or degradation products thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040712 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040910 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20041022 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20041022 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071105 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081105 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081105 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091105 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091105 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101105 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111105 Year of fee payment: 7 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111105 Year of fee payment: 7 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111105 Year of fee payment: 7 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111105 Year of fee payment: 7 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111105 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121105 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121105 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131105 Year of fee payment: 9 |
|
LAPS | Cancellation because of no payment of annual fees |